Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 10/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5538487 | 0.79 | KCNH2 (0.44) | CHRM4KCNH2ALDH1A1TSHRKCNA5 | |
| SCHEMBL5538491 | 0.79 | KCNH2 (0.44) | CHRM4KCNH2ALDH1A1TSHRKCNA5 | |
| SCHEMBL19538665 | 0.76 | TSHR (0.68) | CHRM4ALDH1A1TSHRKCNA5PPARD | |
| SCHEMBL1778054 | 0.73 | CHRM4 (0.49) | CHRM4KCNH2 | |
| SCHEMBL5534678 | 0.73 | KMT2A (0.52) | CHRM4ALDH1A1TSHRKCNA5PPARD | |
| SCHEMBL2093175 | 0.72 | ALDH1A1 (0.50) | CHRM4HTR1AALDH1A1TSHRKCNA5 | |
| SCHEMBL2095351 | 0.71 | HSD17B10 (0.49) | HTR1AKCNH2ALDH1A1TSHRKCNA5 | |
| SCHEMBL2056156 | 0.71 | DRD2 (0.56) | HTR1AKCNH2ALDH1A1TSHR | |
| SCHEMBL2056171 | 0.71 | ALDH1A1 (0.59) | KCNH2ALDH1A1KCNA5 | |
| SCHEMBL2056186 | 0.71 | CHRM4 (0.55) | CHRM4KCNH2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275035-A1 | Nitroimidazole Compounds | JIRICEK JAN | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275035-A1 | Nitroimidazole Compounds | NQO2, NQO1, MT-ND2 | CHRM4 2666/4885HTR1A 4232/4885ADRA1D 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.